IOL Chemicals and Pharmaceuticals reports Q4 FY23 PAT at Rs. 65 Cr
Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
Specialty Chemicals grew 38% YoY for FY23
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
A special technique of jet injection is used to make vaccination almost painless and totally needleless.
CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology
Apollo continues to invest in genomics technology and research for better patient care
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
Subscribe To Our Newsletter & Stay Updated